Q (sonnet): Is KRAS G12C more aggressive than G12D?

═ answer (success)
I can't answer whether KRAS G12C is biologically "more aggressive" than G12D — that's a clinical/biological claim about disease behavior that isn't something cBioPortal's database computes or stores, and it's not a claim I can validate or fabricate from mutation counts alone. Making that determination would require a properly designed survival/outcomes study with statistical testing (e.g., comparing progression-free or overall survival between patient groups, controlling for confounders like cancer type, stage, and treatment), which is outside what I can responsibly conclude here.

What I *can* do is show you the underlying data in cBioPortal so you can explore this yourself:

1. **Frequency and distribution** of G12C vs G12D across studies/cancer types (e.g., G12C is notably enriched in lung adenocarcinoma, G12D in pancreatic and colorectal cancer)
2. **Co-occurring alterations** for each variant
3. **Survival comparison** between patients with G12C vs G12D within a specific cohort, using cBioPortal's Group Comparison Survival tab (which runs the actual log-rank test — something I cannot compute myself)

To make this useful, could you tell me:
- Which cancer type or study are you interested in (e.g., lung adenocarcinoma, pancreatic, colorectal, pan-cancer)?
- Do you want variant frequency, co-mutation patterns, survival comparison, or all three?

For example, if you meant lung adenocarcinoma (where this comparison is most commonly discussed), I can pull up KRAS G12C vs G12D frequencies and link you directly to a survival comparison in that cohort — just confirm the study and I'll proceed.